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The Correlation Between Neuropathy Limitations and Depression  
in Chemotherapy Patients 
 
Melissa Thebeau 
 
ABSTRACT 
 
 This study examined the association between neuropathy limitations and 
depression in chemotherapy patients currently on treatment with a taxane-based, 
platinum-based or plant alkaloid chemotherapy drug.     
The Overall Neuropathy Limitations Scale (ONLS) and the Beck Depression 
Inventory-Short Form (BDI-SF) were used to assess neuropathy limitations and 
depression in 24 chemotherapy patients with reported symptoms of peripheral 
neuropathy.  Average age of patients was 65 years, 66.6% were female, and average 
number of chemotherapy cycles completed was 5.6.  Of the 24 patients, 37.5% of patients 
were on a single agent taxane-based drug, 37.5% of patients were on a taxane-based drug 
with a platinum based drug, 16.6% of patients were on a plant alkaloid, and 8.3% were on 
a combination of a taxane-based and another non-neurotoxic chemotherapy drug.   
 The scores on both the BDI-SF and ONLS were very low.  The mean score on the 
BDI-SF was 4.1 with a standard deviation of 2.7.  The mean score on the ONLS was 2.2 
with a standard deviation of 1.5.  The study showed a non-significant relationship 
between neuropathy limitations and depression in chemotherapy patients.       
 These findings show no association between neuropathy limitations and 
depression.  Although all of these patients had symptoms of peripheral neuropathy, they 
were not severe enough to interfere with daily activities.  The lack of relationship was not 
  v 
unexpected given the low scores on both the BDI-SF and ONLS.  Future research should 
re-evaluate this relationship with a larger, more diverse sample.       
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Chapter One Introduction 
 
Cancer accounts for nearly a quarter of deaths in the United States each year, only 
outranked by heart disease.  In 2009, there were an estimated 1,479,350 new cancer cases 
diagnosed (American Cancer Society, 2010).  Of these patients, nearly half of them will 
receive chemotherapy treatment.  Scientists have made a great deal of progress in 
developing treatments to manage the potential side effects of chemotherapy.  Common 
chemotherapy side effects include infections, nausea and vomiting, hair loss, 
constipation, diarrhea, fatigue, and nerve damage.  Of particular concern, these side 
effects may lead to problems of adherence to treatment and diminished quality of life 
(Gralla, Houlihan, & Messner, 2010). 
One of the side effects of chemotherapy, nervous system damage, can present 
with a unique set of complications.  Peripheral neuropathy (PN) is a complication that 
patients experience when the chemotherapy drugs damage their nerves.  It is often 
characterized by pain, numbness, and tingling in the hands and feet (Gralla, Houlihan, & 
Messner, 2010).  Types of chemotherapy treatments that commonly cause PN include: 
taxanes like paclitaxel, docetaxel and abraxane; platinum drugs such as cisplatin and 
oxaliplatin; and plant alkaloids such as vincristine, vinorelbine and vinblastine (American 
Cancer Society, 2010).   PN may present as pain, numbness and tingling in the 
extremities.  Ototoxicity, changes in vision, blood pressure, and gastrointestinal function 
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infrequently occur (Bakitas, 2007).  These conditions may cause limitations in a patient’s 
daily activities.   
Although effective chemotherapy treatments have been discovered, PN continues 
to be a common complication affecting nerves including the sensory, motor, and 
autonomic systems (Stitham, 2008).  The limitations that PN cause have the potential to 
add an increased level of stress and possible anxiety to cancer patients who already are 
managing many new issues.  Individuals who are experiencing PN may be unable to 
perform many tasks independently, and may be at a higher risk for depression.      
There are several factors that put a cancer patient at risk for depression.  Some of 
these risk factors include living with the disease, medications that are prescribed to 
manage the cancer and side effects, poor support systems, and unrelieved symptoms such 
as pain (Hamilton, 2005).   A paucity of research has been conducted to determine the 
effect of peripheral neuropathy symptoms on the mental health of those diagnosed with 
cancer.   
Problem Statement 
Currently, there is little or no research focusing on the relationship between 
limitations of chemotherapy induced peripheral neuropathy and depressive symptoms.  
The purpose of this study was to determine whether there is a relationship between the 
physical limitations of chemotherapy induced peripheral neuropathy experienced by 
patients with cancer and depressive symptoms. 
This study explored whether patients who are currently under treatment with a 
taxane-based, platinum-based or plant alkaloid chemotherapy and who are suffering from 
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limitations of chemotherapy induced peripheral neuropathy have an increased risk of 
depressive symptoms.  
 
Research Questions 
 
 The following questions guided this study: 
 
1.  What is the level of depression symptomatology experienced by cancer patients  
 
receiving neurotoxic chemotherapy? 
 
2.  What is the level of neuropathy limitations in patients receiving neurotoxic  
 
chemotherapy? 
 
3.  What is the relationship between depressive symptoms and the level of neuropathy  
 
limitations in patients receiving neurotoxic chemotherapy? 
 
Definition of Terms 
 
The following terms are defined for purposes of this study: 
Peripheral Neuropathy – Occurs when nerves are damaged or destroyed and cannot send 
messages from the brain and spinal cord to the muscles, skin, and other parts of the body.  
Symptoms often include:  a sensation of wearing an invisible glove or sock, burning 
sensation or freezing pain, sharp jabbing or electric-like pain, extreme sensitivity to 
touch, difficulty sleeping because of feet and leg pain, loss of balance and coordination, 
muscle weakness, difficulty walking or moving the arms, and may include unusual 
sweating, and abnormalities in blood pressure or pulse.  (Miller, 2007)  
Neuropathy Limitations – Limitations from neuropathy are caused from damaged nerves 
in the sensory, motor and autonomic systems.  These may cause sensation changes, an 
inability to determine joint position which causes lack of coordination, loss of dexterity, 
cramps, falling from legs buckling or tripping over toes.  It may cause lack of dexterity, 
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such as being unable to button a shirt, and lack of muscle control.  Heat or cold 
intolerance, blurred vision, feeling dizzy and/or fainting, and feelings of incomplete 
bladder emptying.  (Stitham, 2008) 
Depression – A mood disorder marked by loss of interest or pleasure in living.  A feeling 
of sadness.  (Davis, 2001) 
Depressive Symptoms – Symptoms of depression may include persistent sadness, 
hopelessness, loss of energy, irritability, excessive sleep or decreased interest in daily 
activities.  (Davis, 2001) 
Significance of the Study 
This study investigates a possible relationship between limitations from 
chemotherapy induced peripheral neuropathy and depression.  PN may cause pain and 
alter patients’ activities of daily living.  As patients’ lose independence with daily 
activities they may become depressed.  Symptoms of PN may limit the ability for an 
individual to remain independent in activities of daily living.  The more severe the 
symptoms of PN become, the more depressed a person may feel.  These feelings of 
depression may lead to non-adherence with treatment, or diminished quality of life.  An 
analysis of previous studies found that depressed patients are three times less likely to 
comply with treatments than patients who are not depressed (McManamy, 2009).     
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Chapter Two Review of Literature 
 
 
This chapter presents the review of literature relevant to this study.  The review of 
literature describes the symptoms of patients with peripheral neuropathy (PN) and the 
effect PN has on quality of life. This reviews empiric evidence of the effects of 
chemotherapy on a patient’s emotional status, and having PN and depressive symptoms.  
Through research, nurses may better understand the relationship between having 
symptoms of PN and depressive symptoms for patients receiving chemotherapy.   
Peripheral Neuropathy and Cancer 
Little is known about the development of peripheral neuropathy.  Depending on 
the chemotherapy, PN side effects can range from a sensory and painful neuropathy to a 
mixed sensory-motor neuropathy with or without autonomic nervous system involvement 
(Sioka & Kyritsis, 2008).  These investigators reviewed the neurotoxicity induced by 
some of the most common chemotherapeutic agents.  The platinum-based drugs were 
found to cause pure sensory neuropathies, the taxane-based drugs caused a mixed sensory 
and motor neuropathy, and the plant alkaloids caused both mixed sensory-motor and 
autonomic neuropathies.   
Bakitas (2007) interviewed 28 patients undergoing a variety of different 
chemotherapy regimens in order to describe the experience and the influence of PN 
symptoms on everyday life.  Patients reported taxane-based chemotherapy induced 
peripheral neuropathy as one of the most distressing treatment-related symptoms and a 
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major cause of alterations in function and quality of life.  Some participants described the 
pain as annoying, distracting, and unpleasant.  When asked about functional ability, 
patients rated the discomfort as a three or four out of ten.  When asked how much the PN 
complicated everyday activities, patients rated it as a seven or eight out of ten.  PN 
interrupts dressing, putting on jewelry, balance, and driving (Bakitis, 2007).  Emotional 
distress was attributed to having to deal with physical symptoms of PN, as well as 
functional and social limitations.    
Peripheral Neuropathy and Diabetes 
Diabetic peripheral neuropathy (DPN) is a common symptom experienced by 
those with advanced diabetes.  Individuals diagnosed with diabetes are not included in 
this study; however, those suffering from PN may report similar symptoms.  In order to 
demonstrate the burden of PN, three studies were reviewed.   
Argoff, Cole, Fishbain, Irving and Mmed (2006) reviewed the current knowledge 
about diabetic peripheral neuropathy pain (DPNP).  They found that up to 50% of 
diabetic patients experienced some degree of PN.  Nearly a third of those with type 1 
diabetes and more than half of those with type 2 diabetes mellitus (DM) had at least one 
neuropathic symptom.  Patients with type 2 DM were more likely to have paresthesia 
and/or burning pain.  The most common presentation of DPNP is pain or tingling in the 
feet.    
Tolle, Xu, and Sadosky (2005) completed a study to determine the burden of 
DPNP.  One-hundred and forty patients with DPNP completed a questionnaire that was 
focused on pain intensity and impact of functioning.  Of the patients who participated, 
57% reported moderate pain and 25% reported severe pain.  Overall, 91% of the patients 
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reported using prescription medication for their DPNP.   Use of medications for anxiety, 
depression, or sleep disturbances were reported for nearly half of the patients.   This 
study concluded that DPNP is associated with substantial patient burden resulting from 
interference with daily functioning.   
The final study (Hoffman, Sadosky, & Alvir, 2008) examined functional and 
health status impairments among patients with DPNP.  The study was conducted in 19 
countries and included 401 diabetic patients with DPNP.  Patients reported DPNP to be 
more severe at night and stated that it frequently disrupts sleep.  The study also showed 
that PN is associated with major life disturbances including more physician office visits, 
interference with daily activities such as ambulating and sleeping, and interference at 
work.    
Depression and Cancer 
Depression in cancer patients is not yet completely understood.  It is not clear 
whether the depression contributes to the cancer, or whether the stress of having cancer 
causes the depression.  No matter how they happen, cancer and depression seem to co-
coincide.  The studies conducted in this area demonstrate that the acceptance of an 
adjuvant chemotherapy regimen relies heavily on whether or not the patient is depressed 
(Colleoni, et al., 2000).   Patients who undergo initial diagnosis of cancer may become 
depressed, which can interfere with treatment decisions and adherence to therapy.  These 
patients may have poorer outcomes because symptoms of depression include fatigue, loss 
of appetite and insomnia.  All of these symptoms make it difficult to continue treatment.  
Results of the study suggested that depression represents a crucial factor for initial 
acceptance of adjuvant chemotherapy, and that by treating the patient’s depression, 
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practitioners may improve the patients’ overall prognosis.  One study (Watson et al., 
1999) of 395 women with breast cancer revealed that at five years there was a 
significantly increased risk of death in women with a high score on the depression scale.  
There was also a correlation for these women between risk of relapse or death in women 
with high scores on the helplessness and hopelessness scale. 
Peripheral Neuropathy and Depression 
Pain severity from PN is associated with depression.  A study reported in 2005 
(Gore et al.) evaluated pain severity, pain-related interference with function, sleep 
impairment, symptom levels of anxiety and depression, and quality of life among patients 
with painful DPN.  Results were based on patient self-reports.  With PN, chronic pain, 
sleep disturbance, and affective disorders often occur simultaneously and often do not 
decline over time.  The primary pain measure in this study looked at the severity of pain 
on a 0 to 10 scale, and its interference with seven factors including general activity, 
mood, walking ability, normal work, relations with others, and enjoyment of life.  Results 
showed that increases in pain resulted in increased difficulty in all seven areas.  The 
Hospital Anxiety and Depression Scale (HADS) measurement tool was used to assess 
anxiety and depression in the patients.  More than half of the patients indicated that they 
were moderately or severely anxious or depressed.  
Summary 
 The review of literature discusses empiric evidence supporting the relationships 
between peripheral neuropathy and depression.  When patients are depressed, judgment 
may be impaired.  Colleoni et al. (2000) showed that depression is a crucial factor for 
initial acceptance of treatment.  Sioka et al. (2008) demonstrated that the most common 
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chemotherapy treatments, including taxane-based, platinum-based and plant alkaloid 
therapies, are all capable of causing neurotoxicity.  Symptoms of PN may contribute to 
depressive symptoms (Bakitas, 2007).  This is also confirmed by Tolle et al. (2005), who 
found that nearly half of patients who were suffering from diabetic peripheral neuropathy 
were also taking medications for anxiety, depression, or sleep disturbances.   
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Chapter Three Methods 
 
This chapter presents the study methods.  The chapter includes descriptions of the  
 
sample, instrumentation, procedures, and data analysis for the study. 
   
Sample 
A sample of 30 adult patients receiving chemotherapy treatment with a taxane-
based, platinum-based or plant alkaloid therapy was sought.  Patients who had reported 
numbness or tingling in their hands and/or feet were included in the study.  Patients who 
were treated for depression prior to chemotherapy were excluded from the study.  
Patients with pre-existing PN from diabetes were excluded from the study.  
Instrumentation 
Beck Depression Inventory-Short Form (BDI-SF) 
The Beck Depression Inventory-Short Form (BDI-SF) was developed in 2003 
(Appendix A).  It assesses the same symptoms as the original Beck Depression Form, 
with a shorter, less burdensome format for the patients.  Rather than the original 21 
questions, the BDI-SF presents nine questions with four possible answers each.  Total 
scores range from zero to 36 with scores as follows:  0 to 10 is not depressed, 12 to 19 is 
depressed and greater than 20 is very depressed (Furlanetto, Mendlowicz, & Bueno, 
2005).  Individual questions of the BDI-SF assess mood, pessimism, sense of failure, self-
dissatisfaction, guilt, punishment, self-dislike, self-accusation, suicidal ideas, crying, 
irritability, social withdrawal, body image, work difficulties, insomnia, fatigue, appetite, 
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weight loss, bodily preoccupation, and loss of libido. The BDI-SF was shown to be a 
valid instrument for the identification of depression, with a sensitivity of 100% and 
specificity of 83.1% (Furlanetto et al., 2005).      
Overall Neuropathy Limitations Scale (ONLS) 
 The ONLS is a scale that is used to assess limitations and disability caused by 
peripheral neuropathy (Appendix B).  The ONLS is composed of two sections that total 
12 questions.  Items 1 to 6 assess neuropathy symptoms in the hands or arms, while items 
7 to 12 assess the same symptoms in the legs and feet.  Each question has three possible 
responses that range from; not affected, affected but not prevented, to prevented.  The 
ONLS is calculated by adding the arm scale total and the leg scale total.  The final score 
can range from 0 (no disability) to 12 (maximum disability).  Acceptable responsiveness 
was shown with the ONLS (Graham, & Hughes, 2006).          
Procedures 
 Patients from one outpatient facility were included in this study. After permission 
was obtained from the facility to include patients in the study (Appendix C), the proposal 
and permission letter were submitted to the USF Institutional Review Board for the 
Protection of Human Subjects (Appendix D).  Following approval, clinic staff identified 
patients who reported numbness and tingling in their hands and/or feet.  The study was 
explained to the patients by the primary investigator and questions answered.  The 
patients signed the informed consent (Appendix E), a copy of the informed consent was 
given to the patient, and he or she was asked to complete the study forms.  The BDI-SF 
was completed by the patient and the ONLS was administered by the primary 
investigator.  The primary investigator asked the questions on the ONLS and the patient 
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answered based on self-perception.  Family members were present during the interview 
with some of the study participants.    
Data Analysis 
The level of depression symptomatology and the limitations from peripheral 
neuropathy symptoms experienced by cancer patients were statistically analyzed using 
means and standard deviations.  The relationship between depressive symptoms and 
limitations of peripheral neuropathy in chemotherapy patients were analyzed using 
Pearson correlation. 
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Chapter Four Results, Discussion, and Conclusions 
This chapter presents the data collection process and the results.  The significance 
of the study, the results, and the relevance to nursing are also discussed.    
Results 
The sample included 24 adult participants. Twenty-eight patients were approached 
and four were excluded because of diabetes or diabetic neuropathy.  Age range was 45-87 
with the average participant age of 65 years.  One participant was 100 years old.  Of the 
24 patients, 37.5% of them were on a single agent taxane-based drug, 37.5% of patients 
were on a combination of a taxane-based drug with a platinum based drug, 16.6% of 
patients were on a plant alkaloid, and 8.3% were on a combination of a taxane-based and 
a non-neurotoxic chemotherapy drug.  All patients had some symptoms of PN.  The 
sample was made up of 66.6% females, and 92% were Caucasian. (Table 1) 
Beck Depression Inventory-Short Form (BDI-SF) 
 The BDI-SF is a patient self-report scale.  Possible scores range from 0 to 36 
where 0 to 10 is not depressed, 11 to 19 is depressed and greater than or equal to 20 is 
very depressed.  In this study the mean score was 4.125.  The lowest score reported was 
one and the highest score was 12. There was only one reported score of 12.  (Table 2) 
Overall Neuropathy Limitations Scale (ONLS) 
 The ONLS scale is calculated by adding the arm scale total and the leg scale total.  
The final score can range from 0 (no disability) to 12 (maximum disability).  In this 
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sample of 24 adults, the mean score was 2.2.  The lowest score reported was zero and the 
highest score was five. (Table 2) 
 
Table 1.  Frequencies and Percentages of Descriptive Demographic Data  
 
Descriptive Demographic Frequency Percentage 
Ethnicity 
   Caucasian-Non-Hispanic 
 
22 
 
92% 
   Caucasian-Hispanic 2 8% 
Gender 
   Male 
 
8 
 
33.3% 
   Female 16 66.6% 
 
 
Table 2.  Means, Standard Deviations, and Ranges for Depression and Neuropathy Scores 
 
Variable N Possible  
Range 
Sample 
 Range 
Mean Standard  
Deviation 
Beck Depression 
Inventory 
24 0-36 1-12      4.1         2.7 
Overall Neuropathy 
Limitations Scale 
24 0-12 0-5      2.2         1.5 
 
Discussion 
Beck Depression Inventory-Short Form (BDI-SF) 
 The BDI-SF is short, and easy to read for patients.  None of the participants 
voiced confusion over any of the questions.  On average it took patients three minutes to 
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complete the short form.  The scores overall were low.  With a possible range of 0 to 36 
the mean score was 4.1.  These results are not consistent with earlier studies reviewed.  
Tolle et al. (2005) found that patients with peripheral neuropathy were so depressed they 
required medications for anxiety, depression and sleep disturbances.      
There are some limitations of the study.  The small sample size, due to time 
limitations, may have excluded some patients with worse symptoms.  Also, patients 
completing the form in the presence of loved ones may not have been truthful or honest 
with their answers.  Some patients do not want their family members to know if they are 
having emotional difficulties.  These limitations may have contributed to the low scores.   
Overall Neuropathy Limitations Scale (ONLS) 
The ONLS is a short survey.  It was administered to the patient by the primary 
investigator.  On average it took patients five minutes to complete the scale.   
With a possible range from 0 to 12 the mean score was 2.2.  Patients with minimal 
neuropathy symptoms were able to participate in the study, which may account for some 
of the low scores.  Patients had received an average of 5.9 cycles of chemotherapy, which 
is a sufficient amount of time for neuropathy symptoms to present.  Scores might be 
higher if symptom severity were measured instead of interference with activity.  Also, the 
ONLS was administered by asking the patient about interference with the various 
activities.  Scores might have differed if the primary investigator were to observe the 
patient doing the activities instead of relying on self-report.    
Relationship Between Peripheral Neuropathy and Depression 
 The patients in this study did not show a significant relationship between their 
neuropathy limitations and depression.  Scores were low on both measures.  This may 
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have contributed to the lack of correlation.  These findings were not consistent with 
previous studies.     
Conclusions 
A study might be done in the future with a few changes. First, the sample size 
should be increased.  This may be improved by collecting data over a longer period of 
time.  This would allow for a wider variety of patients with a wider array of physical and 
mental symptoms.  And second, the search criteria should include only patients with a 
grade two or above PN.  Potentially, these changes would increase scores and result in 
more significant results. 
It is important for nurses to understand the physical and mental effects that 
chemotherapy can have on patients.   Peripheral neuropathy can manifest in many 
different ways and the limitations of ability to perform activities of daily living can be 
devastating.  It makes sense that the loss of autonomy would cause some depressive 
symptoms.  It is for this reason that patients need early detection of symptoms and 
supportive care throughout chemotherapy treatment.   
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Appendix B:  Overall Neuropathy Limitations Scale 
OVERALL NEUROPATHY LIMITATIONS SCALE (ONLS) 
 
Instructions:  The examiner should question and observe the patient in order to determine the answers to the 
following questions.  Note should be made of any other disorder other than peripheral neuropathy which 
limits function at the foot of the page. 
 
ARM SCALE 
 
Does the patient have any symptoms in their hands or arms; e.g. Tingling, numbness or weakness? Yes   
 No    
 
Is the patient affected in their ability to:  Not affected Affected but not prevented
 Prevented 
 
Wash and brush their hair          
 
Turn a key in a lock          
 
Use a knife and fork together         
 
Do or undo buttons or zips          
 
Dress the upper part of their body          
excluding buttons or zips 
 
If all these functions are prevented can the patient make purposeful movements with their hands or arms? 
 Yes    No    
 
Arm Grade 
0= Normal 
1= Minor symptoms in one or both arms but not affecting any of the functions listed 
2= Disability in one or both arms affecting but not preventing any of the functions listed 
3= Disability in one or both arms preventing at least one but not all functions listed 
4= Disability in both arms preventing all functions listed but purposeful movement still possible 
5= Disability in both arms preventing all purposeful movements    
 SCORE=_____ 
 
LEG SCALE 
       Yes  No  N/A 
Does the patient have difficulty running or climbing stairs?      
 
Does the patient have difficulty with walking?       
 
Does their gait look abnormal?         
 
How do they mobilize for about 10 meters (33 feet)?    
 Without aid          
 With one stick or crutch or holding to someone’s arm      
 With two sticks or crutches or one stick or 
 Crutch holding onto someone’s arm or frame      
 With a wheelchair         
 22 
 
If they use a wheelchair, can they stand and walk 1 meter with  
the help of one person?          
 
If they cannot walk as above are they able to make some purposeful  
Movements of their legs; e.g. reposition legs in bed?       
 
Does the patient use ankle or foot braces?      
 
Leg Grade 
0= Walking/climbing stairs/running not affected 
1= Walking/climbing stairs/running is affected, but gait does not look abnormal 
2= Walks independently but gait looks abnormal 
3= Requires unilateral support to walk 10 meters (stick, single crutch, one arm) 
4= Requires bilateral support to walk 10 meters (sticks, crutches, crutch and arm, frame) 
5= Requires wheelchair to travel 10 meters but able to stand and walk 1 meter with the help of one person 
6= Restricted to wheelchair, unable to stand and walk 1 meter with the help of one person, but able to make 
some purposeful leg movements 
7= Restricted to wheelchair or bed most of the day, unable to make any purposeful movements of the legs 
 
Overall Neuropathy Limitations Scale=arm scale (range 0 to 5) + leg scale (range 0 to 7) 
Range 0 (no disability) to 12 (maximum disability)     TOTAL 
SCORE=_____   
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Appendix E:  Informed Consent 
 
 
 
 
 
Informed Consent to Participate in Research 
Information to Consider Before Taking Part in this Research Study 
 
IRB Study # Pro00000265 
 
Researchers at the University of South Florida (USF) study many topics.  To do this, we need the help of 
people who agree to take part in a research study.  This form tells you about this research study. 
We are asking you to take part in a research study that is called: 
The Correlation Between Neuropathy Limitations and Depression in Chemotherapy Patients. 
 
The person who is in charge of this research study is Melissa Thebeau, RN, OCN.  This person is called the 
Principal Investigator.  However, other research staff may be involved and can act on behalf of the person 
in charge.   
 
The research will be done at Florida Cancer Institute-New Hope in New Port Richey, Fl.  
 
 
Purpose of the study 
The purpose of this study is to:  
• The purpose of this study is to find a correlation between chemotherapy-induced peripheral 
neuropathy and depression in chemotherapy patients.  Peripheral Neuropathy is nerve damage in 
your arms and legs and can cause pain numbness and tingling in those body parts. 
• The study is being conducted by a USF graduate nursing student.  All data collection and analysis 
will be overseen by a USF instructor.     
Study Procedures 
If you take part in this study, you will be asked to:  
• 1) Sign this informed consent stating voluntary willingness to participate in the study. 
• 2) Complete the two brief questionnaires:  The Beck Depression Scale and the Overall Neuropathy 
Limitations Scale.   
• 3) The questionnaires will be completed in the chemotherapy infusion room. 
• 4) This one visit is all that is required for this study.  No follow-up visits or phone calls will be 
made.  
• 5) No audio or videotaping will be used.  All forms are confidential and do not contain any 
personal demographic information. 
• 6) If serious depression levels are found, patient may be referred to appropriate resources. 
Alternatives 
You have the alternative to choose not to participate in this research study.  
Benefits 
The benefit of this study includes evaluation of your depression status.  If depression is found, referral to 
appropriate resources may be made.     
Risks or Discomfort 
Risks in this study include any personal discomfort during the interview used to complete the depression 
survey.    
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Compensation 
We will not pay you for the time you volunteer while being in this study.   
Conflict of Interest Statement   
There is no conflict of interest involving the principal investigator in this 
study. 
Privacy and Confidentiality 
We must keep your study records private and confidential; however, certain people may 
need to see your study records.  By law, anyone who looks at your records must keep 
them completely confidential.  The only people who will be allowed to see these records 
are: 
 
• The research team, including the Principal Investigator, study coordinator, 
research nurses, and all other research staff.   
• Certain government and university people who need to know more about the 
study.  For example, individuals who provide oversight on this study may need to 
look at your records. This is done to make sure that we are doing the study in the 
right way.  They also need to make sure that we are protecting your rights and 
your safety.)  These include: 
o The University of South Florida Institutional Review Board (IRB) and the 
staff that work for the IRB.  Other individuals who work for USF that 
provide other kinds of oversight may also need to look at your records.   
o The Department of Health and Human Services (DHHS). 
• Confidentiality may be broken if there is suspicion of threat of harm to self or others.  This 
information would be found during the completion of the Beck Depression Inventory.   
We may publish what we learn from this study.  If we do, we will not let anyone know 
your name.  We will not publish anything else that would let people know who you are.   
Voluntary Participation / Withdrawal 
You should only take part in this study if you want to volunteer.  You should not feel that 
there is any pressure to take part in the study, to please the investigator or the research 
staff.  You are free to participate in this research or withdraw at any time.  There will be 
no penalty or loss of benefits you are entitled to receive if you stop taking part in this 
study.   
New information about the study 
During the course of this study, we may find more information that could be important to you.  This 
includes information that, once learned, might cause you to change your mind about being in the 
study.  We will notify you as soon as possible if such information becomes available. 
Questions, concerns, or complaints 
If you have any questions, concerns or complaints about this study, call the Melissa 
Thebeau, RN, OCN, primary investigator at 727-505-8393. 
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If you have questions about your rights as a participant in this study, general questions, or 
have complaints, concerns or issues you want to discuss with someone outside the 
research, call the Division of Research Integrity and Compliance of the University of 
South Florida at (813) 974-9343. 
  
Consent to Take Part in this Research Study 
It is up to you to decide whether you want to take part in this study.  If you want to take 
part, please sign the form, if the following statements are true. 
I freely give my consent to take part in this study.  I understand that by signing this 
form I am agreeing to take part in research.  I have received a copy of this form to take 
with me. 
 
_____________________________________________ ____________ 
Signature of Person Taking Part in Study Date 
 
_____________________________________________ 
Printed Name of Person Taking Part in Study 
 
 
